SLC44A4 (Solute Carrier Family 44 Member 4)

The impact of SLC44A4 on the extracellular matrix and PI3K/Akt signaling pathway was evaluated by Western blotting.SLC44A4 inhibited the proliferation and migration of OCCC cells in vitro, altered the extracellular matrix, and may inhibit the PI3K/Akt signaling pathway.SLC44A4 overexpression can alter the tumor microenvironment and inhibit the malignant progression of ovarian clear cell carcinoma (OCCC) by remodeling its extracellular matrix. These findings suggest that SLC44A4 may serve as a potential biomarker for evaluating the prognosis of OCCC.

SLC44A4 gene could be a biomarker to predict the prognosis of CRC patients. In addition, this new prognostic model that we proposed can improve the predictive ability to evaluate the prognosis and clinical outcomes of CRC patients.

These findings offer new insights into the molecular mechanisms underlying smoking-induced lung carcinogenesis and progression.

Among prostate-specific membrane antigen (PSMA)-targeted ADCs, ARX517 demonstrates superior safety and more significant prostate-specific antigen (PSA) reductions compared to earlier agents such as MLN2704, PSMA-ADC, and MEDI3726. ADCs targeting B7-H3, such as MGC018 and DB-1311, have also shown antitumor activity. ADCs targeting other antigens, including six-transmembrane epithelial antigen of the prostate (STEAP)1 (DSTP3086S), trophoblast cell surface antigen (TROP)2 (sacituzumab govitecan), and solute carrier (SLC) 44A4 (ASG-5ME), have shown preliminary antitumor activity in early trials but face challenges with insufficient efficacy or toxicity. Tisotumab vedotin (targeting tissue factor) has shown no significant therapeutic response in mCRPC. Meanwhile, disitamab vedotin (HER2-targeted), ABBV-969 (dual PSMA/STEAP1-targeted), and DXC008 (dual PSMA/STEAP1-targeted) are currently under evaluation. Notably, the B7-H3-targeted ADC ifinatamab deruxtecan has initiated an international multicenter phase Ⅲ clinical trial (NCT06925737) for mCRPC in May 2025. This review summarizes recent advances in ADCs targeting key antigens in mCRPC (including PSMA, B7-H3, STEAP1, TROP2, SLC44A4, and others) and explores combination strategies, offering insights to inform the clinical management of this highly lethal disease.

This effect is achieved by promoting mitochondrial E3 ubiquitin ligase 1 (MUL1)-regulated degradation of carnitine palmitoyltransferase 2 (CPT2) via enhancing the interaction between MUL1 and CPT2, without increasing MUL1 expression, which ultimately contributes to the proliferation and metastasis of CRC. Together, SLC44A2 functions as a critical tumor suppressor in CRC and potential therapeutic target in the treatment of this malignancy.

This study provides a comprehensive analysis of TSPAN1's role in endometrial cancer, shedding light on its potential as a key regulator of ferroptosis and glycolysis.

We also assume that the immune system may play a pivotal role in the transition from BOTS to lgOvCa. Given that the BOT.V600E tumors had the lowest number of DM CpGs and DMRs compared to all other groups, when methylome is considered, such tumors might be placed in-between BOT and OvCa.

We established 6 CRRGs-related risk signatures for the prognosis of BC, which is of great value in predicting the prognosis of patients with BC and guiding the treatment for BC.

In PCa lung metastases genes associated with immunogenic responses are upregulated while genes associated with epithelial-mesenchymal transition are down-regulated. This points to a more immunogenic phenotype of PCa lung metastases thus potentially making patients more susceptible to immunotherapeutic approaches.

The SCLC-LM model effectively simulates the pathophysiological process of SCLC metastasis to the leptomeninges. PROTAC EZH2 degrader-1 overcomes chemoresistance in SCLC, suggesting its potential therapeutic value for SCLC LM.

The six-gene model based on NK cell-related gene expression was validated and found to accurately mirror immune microenvironment and predict clinical outcomes, contributing to enhanced risk stratification and therapy response for ccRCC patients.

Conclusions We have been able to validate that the expression changes of the CA5BPB, IYD, SLC44A4 and TMC5 genes could be used as specific biomarkers. On the other hand, we remark that the alteration of the expression profiles in adenocarcinoma is more marked, which would make it subsidiary to a search for biomarkers due to its high genetic load.; Cell and molecular biology; Endoscopy and interventional pulmonology; Epidemiology; Respiratory intensive care